三柏硕（001300）公告，预计2025年1月1日-2025年6月30日归属于上市公司股东的净利润为700万元– 1000万元，同比下降62.14%-45.91%；扣除非经常性损益后的净利润为300万元–600万元，同比下降 75.61%-51.22%。基本每股收益为0.0288元/股–0.0412元/股，同比下降62.14%-45.91%。公司业绩变动主 要受国际贸易政策不确定性及关税调整等不利因素影响，部分客户采购需求收缩，产品海外订单量减 少。 ...

Core Viewpoint - Qingdao Sanbaisuo Health Technology Co., Ltd. has approved the use of up to RMB 500 million of temporarily idle raised funds for cash management, ensuring that it does not affect the normal investment plans and safety of the raised funds [1][3]. Group 1: Cash Management Approval - The company held its 8th meeting of the 2nd Board of Directors and the 2nd Supervisory Board on April 25, 2025, where it approved the proposal for cash management using idle raised funds [1]. - The cash management period is set for 12 months from the date of approval, with individual investment products not exceeding 12 months [1]. Group 2: Investment Products Overview - The company has recently invested in various financial products using idle raised funds, including structured deposits and wealth management products from banks [1][2]. - Specific investments include: - RMB 4 million in a structured deposit with a 1.95% expected annual return [1]. - RMB 6 million in a 29-day structured deposit with an expected return of 1.85% [1]. - RMB 84 million in a structured deposit with a 2.47% expected return [1][2]. Group 3: Impact on Operations - The use of idle raised funds for cash management is aimed at optimizing the efficiency of fund usage without affecting the normal operations of the company's main business [3]. - The cash management strategy is expected to generate additional investment income, enhancing the overall performance of the company and providing better returns for shareholders [3]. Group 4: Compliance and Risk Management - The company emphasizes that the cash management activities comply with relevant regulations and internal control systems, ensuring that there is no change in the intended use of the raised funds [2][3]. - The company has established measures to monitor and control investment risks associated with cash management [3].

证券代码：001300 证券简称：三柏硕 公告编号：2025-034 青岛三柏硕健康科技股份有限公司 关于使用部分暂时闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 二、关联关系说明 公司与华夏银行股份有限公司青岛城阳支行、交通银行股份有限公司青岛分行、 中信银行股份有限公司青岛城阳支行不存在关联关系。 三、投资风险及风险控制措施 青岛三柏硕健康科技股份有限公司（以下简称"公司"）于2025年4月25日分 别召开了第二届董事会第八次会议、第二届监事会第八次会议，审议通过了《关 于使用部分暂时闲置募集资金进行现金管理的议案》，同意在确保不影响募集资 金投资计划正常进行和募集资金安全的情况下，公司使用最高不超过人民币5亿 元的暂时闲置募集资金进行现金管理，使用期限自董事会审议通过之日起12个月 内，单个投资产品的投资期限不超过12个月。额度范围内资金可循环滚动使用。 具体内容详见公司于2025年4月28日披露的《关于使用部分暂时闲置募集资金进 行现金管理的公告》（公告编号：2025-025）。 根据上述决议，公司近期使用闲置募集 ...

Core Points - Sanbai Shuo announced that its wholly-owned subsidiary, Qingdao Yuyang Sports Technology Co., Ltd., applied for a comprehensive credit limit of up to 10 million RMB from the Qingdao branch of Bank of Communications, with Sanbai Shuo providing a maximum guarantee of 11 million RMB [1] - The company and its subsidiary have been approved to apply for a total credit limit of up to 800 million RMB for the year 2025, which includes the current application [1] - The internal approval procedures for the credit and guarantee have been completed, and the amounts are within the previously approved limits, thus no further board or shareholder approval is required [1] Company Financials - Qingdao Yuyang Sports Technology Co., Ltd. was established on January 10, 2018, with a registered capital of 13 million RMB, focusing on the production and sales of leisure sports and fitness equipment [2] - As of March 31, 2025, the company's total assets were 11.0185 million RMB, total liabilities were 9.9709 million RMB, and net assets were 1.0476 million RMB [2] - As of December 31, 2024, the audited financials showed total assets of 13.0494 million RMB, total liabilities of 12.2788 million RMB, and net assets of 0.7706 million RMB [2] Guarantee Details - The guarantee provided by Sanbai Shuo is a joint liability guarantee covering all principal debts, interest, compound interest, penalties, and costs related to the enforcement of claims [2] - As of the announcement date, the total external guarantees provided by the company and its subsidiary amounted to 41 million RMB, which represents 38.54% of the latest audited net assets [2]

近日，公司全资子公司青岛瑜阳体育科技有限公司（以下简称"瑜阳体 育"）与交通银行股份有限公司青岛分行（以下简称"交通银行青岛分行"） 签订《流动资金借款合同》，瑜阳体育向交通银行青岛分行申请不超过1,000万 元人民币综合授信额度；公司与交通银行青岛分行签署《保证合同》，为瑜阳 1 证券代码：001300 证券简称：三柏硕 公告编号：2025-033 青岛三柏硕健康科技股份有限公司 关于全资子公司向银行申请授信额度并由公司为其提供担 保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、授信额度及担保情况概述 青岛三柏硕健康科技股份有限公司（以下简称"公司"）于2025年4月25日 分别召开第二届董事会第八次会议、第二届监事会第八次会议，于2025年5月20 日召开2024年年度股东大会，审议通过了《关于2025年度向银行等金融机构申 请授信额度及担保事项的议案》，同意2025年度公司及全资子公司拟向银行等 金融机构申请额度不超过人民币8亿元的综合授信。在上述授信总额额度内，公 司将根据实际需要由公司及全资子公司以其拥有的资产为其自身融资提供抵押、 质 ...

Core Viewpoint - Qingdao Sanbai Shuo Health Technology Co., Ltd. announced its 2024 annual equity distribution plan, which includes a cash dividend of 0.10 yuan per 10 shares for all shareholders, totaling 2,424,809.14 yuan, with specific conditions regarding share repurchase and tax implications [2][4][6]. Group 1: Equity Distribution Details - The total share capital of the company is 243,775,914 shares, from which 1,295,000 shares held in the repurchase account are excluded, resulting in a base of 242,480,914 shares for the dividend distribution [2][6]. - The cash dividend of 0.10 yuan per 10 shares is inclusive of tax, and the total cash dividend amount is fixed at 2,424,809.14 yuan, with no stock dividends or capital increases from reserves [2][4]. - The dividend distribution plan was approved at the 2024 annual general meeting held on May 20, 2025, and the implementation will occur on June 26, 2025, following the record date of June 25, 2025 [7][8][13]. Group 2: Tax Implications and Payment Method - Different tax rates apply for various categories of shareholders, with specific provisions for Hong Kong investors and domestic investors based on their holding periods [6][10]. - Cash dividends will be directly credited to shareholders' accounts through their custodial securities companies on the payment date [9][10]. - The company assumes all legal responsibilities for any discrepancies in dividend payments due to changes in shareholder accounts during the distribution application period [10]. Group 3: Adjustments and Compliance - The minimum selling price restrictions for major shareholders will be adjusted in accordance with the equity distribution, ensuring compliance with regulatory requirements [11]. - The reference price for ex-dividend trading will be calculated based on the closing price on the record date minus the dividend amount per share [12].

关于通过全资子公司向控股孙公司增加投资的公告 证券代码：001300 证券简称：三柏硕 公告编号：2025-031 青岛三柏硕健康科技股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 青岛三柏硕健康科技股份有限公司（以下简称"公司"）于2025年6月17日 召开第二届董事会第九次会议，审议通过了《关于通过全资子公司向控股孙公司 增加投资的议案》，同意公司以自有资金和自筹资金通过全资子公司OCEAN MASTER INVESTMENTS,INC（以下简称"海硕投资"）向公司控股孙公司三柏硕健 康科技（越南）有限公司（Sportsoul Health Technology (Vietnam) Co.,Ltd） （以下简称"越南三柏硕"）增加投资，现将具体情况公告如下： 一、本次投资情况概述 越南三柏硕系公司控股孙公司，由公司全资子公司海硕投资与CYVERCE LLC （中文译名：塞沃斯公司，以下简称"塞沃斯"）于2025年2月在越南共同出资 设立，注册资本108万美元，其中，海硕投资出资64.80万美元，持股比例60%， 塞沃斯出资43.20万美元，持 ...

青岛三柏硕健康科技股份有限公司 第二届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 青岛三柏硕健康科技股份有限公司（以下简称"公司"）第二届董事会第九 次会议于 2025 年 6 月 17 日以现场和通讯方式召开，会议通知于 2025 年 6 月 13 日以通讯方式送达。经全体董事一致同意豁免本次董事会会议通知时限。会议应 出席董事 7 名，实际出席董事 7 名。公司董事长朱希龙先生主持本次会议。会议 的召集、召开符合《中华人民共和国公司法》等法律法规及《青岛三柏硕健康科 技股份有限公司章程》的规定。公司监事、高级管理人员列席本次会议。 与会董事对本次会议的全部议案进行了充分讨论，审慎表决，形成如下决议： 一、审议通过：《关于通过全资子公司向控股孙公司增加投资的议案》 证券代码：001300 证券简称：三柏硕 公告编号：2025-030 表决情况：7票同意，0票反对，0票弃权。 具体内容详见公司同日刊登在《证券时报》《证券日报》《中国证券报》《上 海证券报》《经济参考报》和巨潮资讯网（www.cninfo.com.cn）的《关于通过 ...

公司2024年年度权益分派方案已获2025年5月20日召开的2024年度股东大会 审议通过。现将权益分派事宜公告如下： 一、股东大会审议通过利润分配方案情况 1、公司2024年度股东大会审议通过的2024年度利润分配预案为：以公司2024 年12月31日公司总股本243,775,914股扣除公司回购专用证券账户上已回购股份 1,295,000股后的总股本242,480,914股为基数，向全体股东每10股派发现金股利 0.10元（含税），共计分配现金红利2,424,809.14元，不送红股，不以公积金转增 股本。如在利润分配预案公告后至实施前，因新增股份上市、股份回购等事项导 致公司总股本发生变化的,公司拟按照现金分红总额固定不变的原则对分配比例 进行相应的调整。 证券代码：001300 证券简称：三柏硕 公告编号：2025-032 青岛三柏硕健康科技股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 根据《深圳证券交易所上市公司自律监管指引第9号-回购股份》的相关规定， 青岛三柏硕健康科技股份有限公司（以 ...

Core Points - The company held its second board meeting on June 17, 2025, with all seven directors present, and the meeting complied with relevant laws and regulations [1][2] - The board unanimously approved the proposal for the wholly-owned subsidiary to increase investment in the controlling subsidiary, with a voting result of 7 votes in favor, 0 against, and 0 abstentions [1][2] - The details of the investment proposal are available in the company's announcement published on various financial news platforms [1]